By The Life Science Report

Source: Streetwise Reports   06/13/2018

Having secured a manufacturing partner for its proprietary antibody candidate, this precision medicine company charts progress toward a Phase 1 trial in Alzheimer’s disease.

ProMIS Neurosciences Inc. (PMN:TSX; ARFXF:OTCQB), in a June 12 press release, announced “the initiation of producer cell line development for PMN310, its lead therapeutic antibody candidate for treatment of Alzheimer’s disease.” Selexis SA, called a “global leader in mammalian (suspension-adapted CHO-K1) cell line generation,” has signed on to manufacture the therapeutic.

Phase 1 clinical trials for PMN310 are slated to begin in the second half of 2019, according to the announcement. The drug targets toxic oligomers, which ProMIS calls a “root cause” of Alzheimer’s disease.

ProMIS President and CEO Dr. Elliot Goldstein stated the company had “recently completed successful affinity maturation of PMN310, which in addition to its unique and highly selective binding profile offers increased opportunity for best in class therapy for Alzheimer’s disease.”

Both Goldstein and Selexis vice president Yemi Onakunle highlighted the synergy between the two companies’ products. “We believe our best-in-class technology can help propel forward this best-in-class therapeutic candidate,” Onakunle stated in the release.

Want to read more Life Sciences Report articles like this? Sign up at www.streetwisereports.com/get-news for our free e-newsletter, and you’ll learn when new articles have been published. To see recent articles and interviews with industry analysts and commentators, visit our Streetwise Interviews page.

Disclosure:
1) Tracy Salcedo compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an employee. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a billboard sponsor of Streetwise Reports: ProMIS Neurosciences. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.

( Companies Mentioned: PMN:TSX; ARFXF:OTCQB,
)